NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky announces it has commenced an investigation of Vital Therapies, Inc. (NASDAQ:VTL) concerning possible violations of federal securities laws. On July 14, 2015, a report was published on Seeking Alpha alleging that the Company’s representations regarding the 90 day overall survival rate for those treated with the Company’s Extracorporeal Liver Assist Device (“ELAD”) were highly misleading, as they included survival data from a patient who received a liver transplant, while no equivalent patient in the control group had received a transplant. The report alleges that this fact was not disclosed in any of the Company’s prior disclosures concerning the Phase 2 VTI-206 study of ELAD. To obtain additional information, go to:
or contact Joseph E. Levi, Esq. either via email at firstname.lastname@example.org or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.